KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Name
Jacks_KRAS and YAP1.pdf
Size
1.65 MB
Format
Adobe PDF
Checksum (MD5)
0cd1384130dbc7e616f58b21197f64b1
Author(s)
Shao, Diane D.
Krall, Elsa B.
Piccioni, Federica
Wang, Xiaoxing
Schinzel, Anna C.
Rosenbluh, Joseph
Kim, Jong W.
Zwang, Yaara
Roberts, Thomas M.
Root, David E.
Date Issued
June 2014
Journal
Cell
Publisher
Elsevier
Citation
Shao, Diane D. et al. “KRAS and YAP1 Converge to Regulate EMT and Tumor Survival.” Cell 158.1 (2014): 171–184.
Version
Author's final manuscript
Abstract
Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.cell.2014.06.004
